Pfizer’s modified messenger RNA influenza vaccine prevented influenza better than an already-available shot, according to newly published results from a clinical trial.
The mRNA, or modRNA, vaccine provided 34.5 percent better protection against laboratory-confirmed influenza associated with influenza-like symptoms when compared to a licensed vaccine, researchers with Pfizer, the Kaiser Permanente Washington Health Research Institute, and other institutions reported on Nov. 19 in the New England Journal of Medicine.
